<p>根据 MarketBeat.com 的报道，Royalty Pharma PLC（纳斯达克代码：RPRX - 获取免费报告）的股票已被目前覆盖该公司的七家券商评定为 “买入” 共识评级。七位投资分析师对该股票给予了买入评级。在过去一年中，覆盖该股票的分析师的平均一年目标价为 53.7143 美元。</p>
<p>获取 <strong>Royalty Pharma</strong> 的提醒：</p>
<ul>
<li>Royalty Pharma 如何在没有生物技术最大风险的情况下产生现金</li>
</ul>
<p>最近，一些分析师对该股票发表了评论。Weiss Ratings 在 5 月 1 日的报告中将 Royalty Pharma 的股票评级从 “买入（b-）” 上调至 “买入（b）”。摩根士丹利在 4 月 10 日的报告中将 Royalty Pharma 的目标价从 61.00 美元上调至 63.00 美元，并给予该股票 “超配” 评级。花旗集团在 5 月 7 日的研究报告中将 Royalty Pharma 的目标价从 50.00 美元上调至 66.00 美元，并给予该股票 “买入” 评级。华尔街 Zen 在 5 月 9 日的研究笔记中将 Royalty Pharma 的股票评级从 “买入” 上调至 “强力买入”。最后，高盛集团在 2 月 12 日的报告中重新发布了对 Royalty Pharma 股票的 “买入” 评级。</p>
<p><strong>阅读我们对 RPRX 的最新分析</strong></p>
<h2>Royalty Pharma 股价下跌 1.0%</h2>
<ul>
<li>1 次试验，2 个业务：Zenas 股票因里程碑数据而上涨</li>
</ul>
<p>Royalty Pharma 股票在周五开盘价为 52.85 美元。该公司的债务与股本比率为 0.86，流动比率为 2.66，速动比率为 2.66。Royalty Pharma 的一年低点为 32.15 美元，一年高点为 53.47 美元。该股票的市值为 304.3 亿美元，市盈率为 35.95，市盈增长比率为 1.47，贝塔值为 0.40。该公司的 50 日移动平均线为 48.31 美元，200 日移动平均线为 43.35 美元。</p>
<p>Royalty Pharma（纳斯达克代码：RPRX - 获取免费报告）最近在 5 月 6 日发布了其财报。这家生物制药公司报告季度每股收益为 1.30 美元，超出分析师共识预期的 1.22 美元，超出幅度为 0.08 美元。该公司在本季度的收入为 6.31 亿美元，而分析师预期为 8.8169 亿美元。Royalty Pharma 的股本回报率为 29.25%，净利润率为 33.88%。平均而言，卖方分析师预测 Royalty Pharma 在当前年度的每股收益为 5.05。</p>
<h2>Royalty Pharma 分红公告</h2>
<ul>
<li>4 只医疗股大幅上涨——还有更多上涨空间</li>
</ul>
<p>该公司最近还披露了一项季度分红，将于 6 月 10 日支付。5 月 15 日的登记投资者将获得每股 0.235 美元的分红。这相当于年化 0.94 美元的分红，收益率为 1.8%。除息日为 5 月 15 日。Royalty Pharma 的分红支付比率为 63.95%。</p>
<h2>Royalty Pharma 内部买卖情况</h2>
<p>在相关消息中，董事 Gregory Norden 于 5 月 14 日星期四出售了 3,045 股公司的股票，交易价格为每股 53.00 美元，总交易额为 161,385.00 美元。出售后，该董事直接持有公司 191,803 股，估值约为 10,165,559 美元。此次交易使其持股比例减少了 1.56%。该交易已在向 SEC 提交的文件中披露，相关信息可通过 SEC 网站访问。该交易是在预先安排的 10b5-1 交易计划下执行的。此外，首席财务官 Terrance P. Coyne 于 4 月 28 日星期二出售了 34,791 股公司的股票，交易价格为每股 49.78 美元，总交易额为 1,731,895.98 美元。有关此次出售的更多细节可在官方 SEC 披露中找到。过去三个月，内部人士共出售了价值 7,512,360 美元的 155,893 股公司股票。目前，18.84% 的股票由公司内部人士持有。</p>
<h2>机构资金流入和流出</h2>
<p>机构投资者和对冲基金最近调整了对该公司的持股。LM Advisors LLC 在第四季度购买了 Royalty Pharma 的新股份，价值 26,000 美元。Lloyd Advisory Services LLC 在第四季度购买了 Royalty Pharma 的新股份，价值约 30,000 美元。Smartleaf Asset Management LLC 在第三季度将其在 Royalty Pharma 的持股增加了 868.1%。Smartleaf Asset Management LLC 目前持有该生物制药公司 881 股股票，价值 31,000 美元，此前在该期间内又购买了 790 股。Private Trust Co. NA 在第四季度将其在 Royalty Pharma 的持股增加了 52.9%。Private Trust Co. NA 目前持有该生物制药公司 832 股股票，价值 32,000 美元，此前在上个季度又购买了 288 股。最后，Blue Trust Inc. 在第一季度将其在 Royalty Pharma 的持股增加了 173.4%。Blue Trust Inc. 目前持有该生物制药公司 689 股股票，价值 33,000 美元，此前在该期间内又购买了 437 股。对冲基金和其他机构投资者持有该公司 54.35% 的股票。</p>
<h2>Royalty Pharma 公司简介</h2>
<p>（获取免费报告）</p>
<p>Royalty Pharma plc 是一家专注于生物制药特许权融资的公司，收购生物制药特许权利益，并为药物开发者和权利持有者提供非稀释融资。该公司购买与已批准和晚期药品及生物技术产品相关的未来特许权流、里程碑付款和其他收入权利。通过提前支付这些权利的对价，Royalty Pharma 旨在产生与多样化药物组合的商业表现相关的长期现金流。</p>
<p>该公司的交易结构包括直接特许权购买、结构化融资和根据创新公司、学术机构和投资者的需求量身定制的里程碑安排。</p>
<h2>推荐阅读</h2>
<ul>
<li>我们更看好的五只股票超过 Royalty Pharma</li>
<li>Peloton 股票在乐观的财报发布后回吐涨幅</li>
<li>MarketBeat 周回顾 – 05/11 - 05/15</li>
<li>Viking 股票创下历史新高——基本面信号显示未来还有更多</li>
<li>Datavalut 获得关注：现在出售的五个理由</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9UlBSWA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="600" height="385" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9UlBSWA"/></p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。如对本故事有任何问题或意见，请发送邮件至 contact@marketbeat.com.</em></p>
<h2>你现在应该投资 1,000 美元在 Royalty Pharma 吗？</h2>
<p>在考虑 Royalty Pharma 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前... 而 Royalty Pharma 并不在名单上。</p>
<p>虽然 Royalty Pharma 目前在分析师中有买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

RPRX

动态生物技术与基因组 ETF - Invesco

标普全球医疗股指数 ETF - iShares

<p>Royalty Pharma PLC（纳斯达克代码：RPRX）获得了七家券商的一致 “买入” 评级。分析师设定的平均一年目标价为 53.71 美元。最近的升级包括摩根士丹利将目标价从 61 美元上调至 63 美元，花旗集团将目标价从 50 美元上调至 66 美元。该公司报告的每股收益为 1.30 美元，超出预期，并宣布每股季度分红为 0.235 美元。内部人士进行了股票出售，董事 Gregory Norden 和首席财务官 Terrance P. Coyne 出售了大量股份</p>

<p>Shares of Royalty Pharma PLC (NASDAQ:RPRX - Get Free Report) have been assigned a consensus rating of &#34;Buy&#34; from the seven brokerages that are currently covering the company, MarketBeat.com reports. Seven investment analysts have rated the stock with a buy rating. The average 1-year target price among analysts that have covered the stock in the last year is $53.7143.</p>
<div class="lb-trans"><p>根据 MarketBeat.com 的报道，Royalty Pharma PLC（纳斯达克代码：RPRX - 获取免费报告）的股票已被目前覆盖该公司的七家券商评定为 “买入” 共识评级。七位投资分析师对该股票给予了买入评级。在过去一年中，覆盖该股票的分析师的平均一年目标价为 53.7143 美元。</p>
</div><p>Get <strong>Royalty Pharma</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Royalty Pharma</strong> 的提醒：</p>
</div><ul>
<li>How Royalty Pharma Prints Cash Without Biotech's Biggest Risks</li>
</ul>
<div class="lb-trans"><ul>
<li>Royalty Pharma 如何在没有生物技术最大风险的情况下产生现金</li>
</ul>
</div><p>A number of analysts have recently commented on the stock. Weiss Ratings raised shares of Royalty Pharma from a &#34;buy (b-)&#34; rating to a &#34;buy (b)&#34; rating in a report on Friday, May 1st. Morgan Stanley raised their target price on shares of Royalty Pharma from $61.00 to $63.00 and gave the stock an &#34;overweight&#34; rating in a report on Friday, April 10th. Citigroup lifted their target price on shares of Royalty Pharma from $50.00 to $66.00 and gave the stock a &#34;buy&#34; rating in a research report on Thursday, May 7th. Wall Street Zen upgraded shares of Royalty Pharma from a &#34;buy&#34; rating to a &#34;strong-buy&#34; rating in a research note on Saturday, May 9th. Finally, The Goldman Sachs Group reissued a &#34;buy&#34; rating on shares of Royalty Pharma in a report on Thursday, February 12th.</p>
<div class="lb-trans"><p>最近，一些分析师对该股票发表了评论。Weiss Ratings 在 5 月 1 日的报告中将 Royalty Pharma 的股票评级从 “买入（b-）” 上调至 “买入（b）”。摩根士丹利在 4 月 10 日的报告中将 Royalty Pharma 的目标价从 61.00 美元上调至 63.00 美元，并给予该股票 “超配” 评级。花旗集团在 5 月 7 日的研究报告中将 Royalty Pharma 的目标价从 50.00 美元上调至 66.00 美元，并给予该股票 “买入” 评级。华尔街 Zen 在 5 月 9 日的研究笔记中将 Royalty Pharma 的股票评级从 “买入” 上调至 “强力买入”。最后，高盛集团在 2 月 12 日的报告中重新发布了对 Royalty Pharma 股票的 “买入” 评级。</p>
</div><p><strong>Read Our Latest Analysis on RPRX</strong></p>
<div class="lb-trans"><p><strong>阅读我们对 RPRX 的最新分析</strong></p>
</div><h2>Royalty Pharma Trading Down 1.0%</h2>
<div class="lb-trans"><h2>Royalty Pharma 股价下跌 1.0%</h2>
</div><ul>
<li>1 Trial, 2 Franchises: Zenas Stock Climbs on Landmark Data</li>
</ul>
<div class="lb-trans"><ul>
<li>1 次试验，2 个业务：Zenas 股票因里程碑数据而上涨</li>
</ul>
</div><p>Royalty Pharma stock opened at $52.85 on Friday. The company has a debt-to-equity ratio of 0.86, a current ratio of 2.66 and a quick ratio of 2.66. Royalty Pharma has a one year low of $32.15 and a one year high of $53.47. The stock has a market capitalization of $30.43 billion, a PE ratio of 35.95, a price-to-earnings-growth ratio of 1.47 and a beta of 0.40. The business's fifty day moving average is $48.31 and its 200 day moving average is $43.35.</p>
<div class="lb-trans"><p>Royalty Pharma 股票在周五开盘价为 52.85 美元。该公司的债务与股本比率为 0.86，流动比率为 2.66，速动比率为 2.66。Royalty Pharma 的一年低点为 32.15 美元，一年高点为 53.47 美元。该股票的市值为 304.3 亿美元，市盈率为 35.95，市盈增长比率为 1.47，贝塔值为 0.40。该公司的 50 日移动平均线为 48.31 美元，200 日移动平均线为 43.35 美元。</p>
</div><p>Royalty Pharma (NASDAQ:RPRX - Get Free Report) last issued its earnings results on Wednesday, May 6th. The biopharmaceutical company reported $1.30 earnings per share for the quarter, topping analysts' consensus estimates of $1.22 by $0.08. The business had revenue of $631.00 million during the quarter, compared to analyst estimates of $881.69 million. Royalty Pharma had a return on equity of 29.25% and a net margin of 33.88%. On average, sell-side analysts predict that Royalty Pharma will post 5.05 EPS for the current year.</p>
<div class="lb-trans"><p>Royalty Pharma（纳斯达克代码：RPRX - 获取免费报告）最近在 5 月 6 日发布了其财报。这家生物制药公司报告季度每股收益为 1.30 美元，超出分析师共识预期的 1.22 美元，超出幅度为 0.08 美元。该公司在本季度的收入为 6.31 亿美元，而分析师预期为 8.8169 亿美元。Royalty Pharma 的股本回报率为 29.25%，净利润率为 33.88%。平均而言，卖方分析师预测 Royalty Pharma 在当前年度的每股收益为 5.05。</p>
</div><h2>Royalty Pharma Dividend Announcement</h2>
<div class="lb-trans"><h2>Royalty Pharma 分红公告</h2>
</div><ul>
<li>4 Healthcare Stocks With Massive Gains—and More to Come</li>
</ul>
<div class="lb-trans"><ul>
<li>4 只医疗股大幅上涨——还有更多上涨空间</li>
</ul>
</div><p>The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, June 10th. Investors of record on Friday, May 15th will be given a dividend of $0.235 per share. This represents a $0.94 dividend on an annualized basis and a yield of 1.8%. The ex-dividend date is Friday, May 15th. Royalty Pharma's dividend payout ratio is 63.95%.</p>
<div class="lb-trans"><p>该公司最近还披露了一项季度分红，将于 6 月 10 日支付。5 月 15 日的登记投资者将获得每股 0.235 美元的分红。这相当于年化 0.94 美元的分红，收益率为 1.8%。除息日为 5 月 15 日。Royalty Pharma 的分红支付比率为 63.95%。</p>
</div><h2>Insider Buying and Selling at Royalty Pharma</h2>
<div class="lb-trans"><h2>Royalty Pharma 内部买卖情况</h2>
</div><p>In related news, Director Gregory Norden sold 3,045 shares of the business's stock in a transaction that occurred on Thursday, May 14th. The shares were sold at an average price of $53.00, for a total transaction of $161,385.00. Following the completion of the sale, the director directly owned 191,803 shares in the company, valued at approximately $10,165,559. The trade was a 1.56% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Terrance P. Coyne sold 34,791 shares of the business's stock in a transaction that occurred on Tuesday, April 28th. The shares were sold at an average price of $49.78, for a total transaction of $1,731,895.98. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 155,893 shares of company stock worth $7,512,360 in the last three months. 18.84% of the stock is currently owned by company insiders.</p>
<div class="lb-trans"><p>在相关消息中，董事 Gregory Norden 于 5 月 14 日星期四出售了 3,045 股公司的股票，交易价格为每股 53.00 美元，总交易额为 161,385.00 美元。出售后，该董事直接持有公司 191,803 股，估值约为 10,165,559 美元。此次交易使其持股比例减少了 1.56%。该交易已在向 SEC 提交的文件中披露，相关信息可通过 SEC 网站访问。该交易是在预先安排的 10b5-1 交易计划下执行的。此外，首席财务官 Terrance P. Coyne 于 4 月 28 日星期二出售了 34,791 股公司的股票，交易价格为每股 49.78 美元，总交易额为 1,731,895.98 美元。有关此次出售的更多细节可在官方 SEC 披露中找到。过去三个月，内部人士共出售了价值 7,512,360 美元的 155,893 股公司股票。目前，18.84% 的股票由公司内部人士持有。</p>
</div><h2>Institutional Inflows and Outflows</h2>
<div class="lb-trans"><h2>机构资金流入和流出</h2>
</div><p>Institutional investors and hedge funds have recently modified their holdings of the business. LM Advisors LLC purchased a new stake in shares of Royalty Pharma in the 4th quarter worth $26,000. Lloyd Advisory Services LLC. bought a new stake in Royalty Pharma during the fourth quarter valued at about $30,000. Smartleaf Asset Management LLC grew its holdings in Royalty Pharma by 868.1% during the third quarter. Smartleaf Asset Management LLC now owns 881 shares of the biopharmaceutical company's stock valued at $31,000 after purchasing an additional 790 shares during the period. Private Trust Co. NA increased its position in Royalty Pharma by 52.9% in the fourth quarter. Private Trust Co. NA now owns 832 shares of the biopharmaceutical company's stock worth $32,000 after buying an additional 288 shares in the last quarter. Finally, Blue Trust Inc. raised its stake in shares of Royalty Pharma by 173.4% in the first quarter. Blue Trust Inc. now owns 689 shares of the biopharmaceutical company's stock worth $33,000 after buying an additional 437 shares during the period. Hedge funds and other institutional investors own 54.35% of the company's stock.</p>
<div class="lb-trans"><p>机构投资者和对冲基金最近调整了对该公司的持股。LM Advisors LLC 在第四季度购买了 Royalty Pharma 的新股份，价值 26,000 美元。Lloyd Advisory Services LLC 在第四季度购买了 Royalty Pharma 的新股份，价值约 30,000 美元。Smartleaf Asset Management LLC 在第三季度将其在 Royalty Pharma 的持股增加了 868.1%。Smartleaf Asset Management LLC 目前持有该生物制药公司 881 股股票，价值 31,000 美元，此前在该期间内又购买了 790 股。Private Trust Co. NA 在第四季度将其在 Royalty Pharma 的持股增加了 52.9%。Private Trust Co. NA 目前持有该生物制药公司 832 股股票，价值 32,000 美元，此前在上个季度又购买了 288 股。最后，Blue Trust Inc. 在第一季度将其在 Royalty Pharma 的持股增加了 173.4%。Blue Trust Inc. 目前持有该生物制药公司 689 股股票，价值 33,000 美元，此前在该期间内又购买了 437 股。对冲基金和其他机构投资者持有该公司 54.35% 的股票。</p>
</div><h2>Royalty Pharma Company Profile</h2>
<div class="lb-trans"><h2>Royalty Pharma 公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Royalty Pharma plc is a specialty finance company that acquires biopharmaceutical royalty interests and provides non-dilutive financing to drug developers and rights holders. The firm purchases future royalty streams, milestone-contingent payments and other revenue rights linked to approved and late-stage pharmaceutical and biotechnology products. By paying upfront consideration for these rights, Royalty Pharma seeks to generate long-term cash flows tied to the commercial performance of a diversified portfolio of medicines.</p>
<div class="lb-trans"><p>Royalty Pharma plc 是一家专注于生物制药特许权融资的公司，收购生物制药特许权利益，并为药物开发者和权利持有者提供非稀释融资。该公司购买与已批准和晚期药品及生物技术产品相关的未来特许权流、里程碑付款和其他收入权利。通过提前支付这些权利的对价，Royalty Pharma 旨在产生与多样化药物组合的商业表现相关的长期现金流。</p>
</div><p>The company's transaction structures include outright royalty purchases, structured financings and milestone arrangements tailored to the needs of innovator companies, academic institutions and investors.</p>
<div class="lb-trans"><p>该公司的交易结构包括直接特许权购买、结构化融资和根据创新公司、学术机构和投资者的需求量身定制的里程碑安排。</p>
</div><h2>Recommended Stories</h2>
<div class="lb-trans"><h2>推荐阅读</h2>
</div><ul>
<li>Five stocks we like better than Royalty Pharma</li>
<li>Peloton Stock Gives Back Gains After Upbeat Earnings Report</li>
<li>MarketBeat Week in Review – 05/11 - 05/15</li>
<li>Viking Sails to All-Time Highs—Fundamentals Signal More to Come</li>
<li>Datavalut Gains Traction: 5 Reasons to Sell Now</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票超过 Royalty Pharma</li>
<li>Peloton 股票在乐观的财报发布后回吐涨幅</li>
<li>MarketBeat 周回顾 – 05/11 - 05/15</li>
<li>Viking 股票创下历史新高——基本面信号显示未来还有更多</li>
<li>Datavalut 获得关注：现在出售的五个理由</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9UlBSWA" alt="" original-src="https://www.marketbeat.com/scripts/RatingsChart.ashx?Prefix=NASDAQ&amp;Symbol=RPRX"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。如对本故事有任何问题或意见，请发送邮件至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in Royalty Pharma Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Royalty Pharma 吗？</h2>
</div><p>Before you consider Royalty Pharma, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Royalty Pharma 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Royalty Pharma wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前... 而 Royalty Pharma 并不在名单上。</p>
</div><p>While Royalty Pharma currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Royalty Pharma 目前在分析师中有买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Royalty Pharma PLC (NASDAQ:RPRX) Given Consensus Rating of "Buy" by Analysts

Market Beat

Royalty Pharma PLC - CL

标普生物技术 3 倍做多 - Direxion

基因改革 ETF - ARK

医药突破 ETF - ALPS

纽交所高增长板生物技术指数 ETF - First Trust

纳斯达克生物科技指数 ETF - iShares Nasdaq

2 倍做多纳斯达克生物技术 ETF - ProShares

生物科技 ETF - VanEck Vectors

标普生物技术 ETF - SPDR

医疗业 ETF - Vanguard

美国制药 ETF - iShares

医疗业 ETF - SPDR

摩根士丹利

花旗

高盛

Zenas Biopharma

MORGAN STANLEY DEP SHS EA REP 1/1000 SHS NON CUM PFD O

MORGAN STANLEY DEP SHS REPSTG 1/1000TH PFD SER Q

MORGAN STANLEY DEP SHS REPS 1/1000 7.125% PFD E

MORGAN STANLEY NON-CUM DEP SH REP 1/1000 PFD SER I

MORGAN STANLEY 4.875 DEP SHS REP 1/1000 NCUM PFD SR L

MORGAN STANLEY 6.5%DEP SHS REPSTG 1/1000 NON CUM SER P

MORGAN STANLEY DEP SHS REPS 1/1000 PFD SER 'A'

MORGAN STANLEY DEP SHS REPR 1/1000TH INT PFD SER 'F' FX

MORGAN STANLEY DEP SHS REP 1/1000 NON-CUM PFD STK SER K

CITIGROUP INC 6.250 NON CUM SER II PFD WI

GS Hldg R

分析师给予 Royalty Pharma PLC（纳斯达克股票代码：RPRX）“买入” 的一致评级